SCHEMBL3341282

SCHEMBL3341282

CC(=O)Nc1ccc(-c2ccc3nc(N)nc(OCc4ccccc4)c3c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 3/20 0.54
JAK2 O60674 1/20 0.46
FDPS P14324 1/20 0.46
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
PPIA P62937 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
KDM4E B2RXH2 4/20 0.44
MAP4K4 O95819 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CSF1R P07333 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PDE10A Q9Y233 1/20 0.43
MTOR P42345 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5129183 0.94 GHSR (0.49) GHSRJAK2FDPSCYP11B1CYP11B2
SCHEMBL3340079 0.88 JAK2 (0.47) GHSRJAK2FDPSCYP11B1CYP11B2
SCHEMBL3335192 0.87 TTK (0.47) GHSRFDPSKMT2AMEN1KDM4E
SCHEMBL3340775 0.85 MAPK10 (0.44) GHSRFDPSKMT2AMEN1KDM4E
SCHEMBL3335286 0.85 RAB9A (0.56) JAK2FDPSCYP11B1CYP11B2PPIA
SCHEMBL3335821 0.84 HPGD (0.44) GHSRFDPSKMT2AMEN1MAP4K4
SCHEMBL3337175 0.84 MOK (0.46) GHSRFDPSKMT2AMEN1KDM4E
SCHEMBL3335960 0.83 KMT2A (0.46) GHSRKMT2AMEN1KDM4EMAP4K4
SCHEMBL3335708 0.83 JAK2 (0.47) JAK2KMT2AMEN1MAP4K4SMN1; SMN2
SCHEMBL3340067 0.83 MAPK10 (0.43) GHSRFDPSMAP4K4CSF1RSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 GHSR 2477/4885JAK2 1107/4885FDPS 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.